Patents by Inventor Enrique Rodriguez-Boulan

Enrique Rodriguez-Boulan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS OF MATTER WITH ACTIVITY TO REMOVE LIPOFUSCIN FROM RETINAL CELLS
    Publication number: 20220118002
    Abstract: The present disclosure relates generally to compositions and methods for the treatment of eye diseases (e.g., retinopathies), and more particularly, to treatment of eye diseases associated with retinal cell lipofuscin accumulation.
    Type: Application
    Filed: March 3, 2020
    Publication date: April 21, 2022
    Applicant: Cornell University
    Inventors: Marcelo M. Nociari, Enrique Rodriguez Boulan
  • Treatments for retinal disorders
    Patent number: 10849922
    Abstract: The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: December 1, 2020
    Assignee: CORNELL UNIVERSITY
    Inventors: Enrique Rodriguez-Boulan, Marcelo Nociari
  • TREATMENTS FOR RETINAL DISORDERS
    Publication number: 20200121711
    Abstract: The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.
    Type: Application
    Filed: October 7, 2019
    Publication date: April 23, 2020
    Applicant: Cornell University
    Inventors: Enrique RODRIGUEZ-BOULAN, Marcelo NOCIARI
  • Treatments for retinal disorders
    Patent number: 10463687
    Abstract: The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: November 5, 2019
    Assignee: CORNELL UNIVERSITY
    Inventors: Enrique Rodriguez-Boulan, Marcelo Nociari
  • TREATMENTS FOR RETINAL DISORDERS
    Publication number: 20140038918
    Abstract: The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.
    Type: Application
    Filed: January 20, 2012
    Publication date: February 6, 2014
    Applicant: CORNELL UNIVERSITY
    Inventors: Enrique Rodriguez-Boulan, Marcelo Nociari